- Services
- Assay kits
Hemato Oncology Testing Market size was valued at 2.5 billion in 2022 and is poised to grow at a CAGR of 14.8% from 2023 to 2029. There is a high rise in the number of patients suffering from blood and tumor diseases, which has been the key reason for substantial growth in the hemato-oncology market. Growing hematological cancer prevalence, developing partnerships to create new assays, and growing knowledge of customized medicines. In addition, the recent increase in the geriatric population is another integral factor driving the global demand for hemato-oncology. However, it is expected that unclear reimbursements in various regions will hinder market development. The report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics, regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.
Hemato Oncology Testing Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
14.8%
Largest Market
Europe
Fastest Growing Market
North-America
Hemato Oncology Testing Market Dynamics
The key trend is the discovery and development of new tests and therapies, with companies operating in the global market for hemato oncology testing continuing to compete. Their growing engagement in partnerships and alliances is proving to be very advantageous for the growth of the business. Nonetheless, the high demand for PCR and NGS technologies for testing and diagnosis of hemato oncology would in the long run normalize the effect of these restricting factors.
North-America Got Significant Share
Hemato Oncology Testing Market Regional Analysis
For the past few years, North America has been leading the global economy. This regional market has been assisted by the availability of advanced medical and healthcare facilities and the early adoption of advanced technologies. In the years to come, the involvement of key players and continuous study in the field of oncology will continue to drive the demand for North American hemato oncology testing.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- In May 2019, Adaptive Biotechnologies collaborated with Sanofi, SA. to utilize Adaptive’s clonoSEQ Assay to measure MRD status in response to isatuximab.
- In July 2019, Abbott Laboratories received FDA approval for its Abbott RealTime IDH1 kit.
- In May 2019, Invivoscribe, Inc. partnered with the American University of Beirut Medical Center (AUBMC) to create a new center of excellence facility in the Middle East.
Hemato Oncology Testing Market Segmentation
By Product Type
By Cancer Type
- Leukemia
- Acute myeloid leukemia
- Acute lymphocytic leukemia
- Lymphoma
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Others
By Technology
- PCR
- IHC
- NGS
- Cytogenetics
- Others
By End User
- Clinical laboratories
- Hospitals
- Academic & Research Institutes
- Other End Users
Frequently Asked Questions
The hemato oncology testing market size was valued at USD 2.5 billion in 2022
Increasing Incidence of Hematologic Cancer Source
North America is the fastest-growing for hemato oncology testing market
| 1. Executive Summary |
| 2. Global Hemato Oncology Testing Market Introduction |
| 2.1.Global Hemato Oncology Testing Market - Taxonomy |
| 2.2.Global Hemato Oncology Testing Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Cancer Type |
| 2.2.3.Technology |
| 2.2.4.End User |
| 2.2.5.Region |
| 3. Global Hemato Oncology Testing Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Hemato Oncology Testing Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Hemato Oncology Testing Market By Product Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Services |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Assay kits |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6. Global Hemato Oncology Testing Market By Cancer Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Leukemia |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Acute myeloid leukemia |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Acute lymphocytic leukemia |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Lymphoma |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Non-Hodgkin lymphoma |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Hodgkin lymphoma |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7. Global Hemato Oncology Testing Market By Technology, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. PCR |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. IHC |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. NGS |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Cytogenetics |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Others |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. Global Hemato Oncology Testing Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Clinical laboratories |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Hospitals |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Academic & Research Institutes |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Other End Users |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9. Global Hemato Oncology Testing Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. North America Hemato Oncology Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Services |
| 10.1.2.Assay kits |
| 10.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Leukemia |
| 10.2.2.Acute myeloid leukemia |
| 10.2.3.Acute lymphocytic leukemia |
| 10.2.4.Lymphoma |
| 10.2.5.Non-Hodgkin lymphoma |
| 10.2.6.Hodgkin lymphoma |
| 10.2.7.Others |
| 10.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.PCR |
| 10.3.2.IHC |
| 10.3.3.NGS |
| 10.3.4.Cytogenetics |
| 10.3.5.Others |
| 10.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Clinical laboratories |
| 10.4.2.Hospitals |
| 10.4.3.Academic & Research Institutes |
| 10.4.4.Other End Users |
| 10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11. Europe Hemato Oncology Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Services |
| 11.1.2.Assay kits |
| 11.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Leukemia |
| 11.2.2.Acute myeloid leukemia |
| 11.2.3.Acute lymphocytic leukemia |
| 11.2.4.Lymphoma |
| 11.2.5.Non-Hodgkin lymphoma |
| 11.2.6.Hodgkin lymphoma |
| 11.2.7.Others |
| 11.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.PCR |
| 11.3.2.IHC |
| 11.3.3.NGS |
| 11.3.4.Cytogenetics |
| 11.3.5.Others |
| 11.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Clinical laboratories |
| 11.4.2.Hospitals |
| 11.4.3.Academic & Research Institutes |
| 11.4.4.Other End Users |
| 11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12. Asia Pacific (APAC) Hemato Oncology Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Services |
| 12.1.2.Assay kits |
| 12.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Leukemia |
| 12.2.2.Acute myeloid leukemia |
| 12.2.3.Acute lymphocytic leukemia |
| 12.2.4.Lymphoma |
| 12.2.5.Non-Hodgkin lymphoma |
| 12.2.6.Hodgkin lymphoma |
| 12.2.7.Others |
| 12.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.PCR |
| 12.3.2.IHC |
| 12.3.3.NGS |
| 12.3.4.Cytogenetics |
| 12.3.5.Others |
| 12.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Clinical laboratories |
| 12.4.2.Hospitals |
| 12.4.3.Academic & Research Institutes |
| 12.4.4.Other End Users |
| 12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13. Middle East and Africa (MEA) Hemato Oncology Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Services |
| 13.1.2.Assay kits |
| 13.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Leukemia |
| 13.2.2.Acute myeloid leukemia |
| 13.2.3.Acute lymphocytic leukemia |
| 13.2.4.Lymphoma |
| 13.2.5.Non-Hodgkin lymphoma |
| 13.2.6.Hodgkin lymphoma |
| 13.2.7.Others |
| 13.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.PCR |
| 13.3.2.IHC |
| 13.3.3.NGS |
| 13.3.4.Cytogenetics |
| 13.3.5.Others |
| 13.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Clinical laboratories |
| 13.4.2.Hospitals |
| 13.4.3.Academic & Research Institutes |
| 13.4.4.Other End Users |
| 13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14. Latin America Hemato Oncology Testing Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 14.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Services |
| 14.1.2.Assay kits |
| 14.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Leukemia |
| 14.2.2.Acute myeloid leukemia |
| 14.2.3.Acute lymphocytic leukemia |
| 14.2.4.Lymphoma |
| 14.2.5.Non-Hodgkin lymphoma |
| 14.2.6.Hodgkin lymphoma |
| 14.2.7.Others |
| 14.3. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.PCR |
| 14.3.2.IHC |
| 14.3.3.NGS |
| 14.3.4.Cytogenetics |
| 14.3.5.Others |
| 14.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Clinical laboratories |
| 14.4.2.Hospitals |
| 14.4.3.Academic & Research Institutes |
| 14.4.4.Other End Users |
| 14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Hoffmann-La Roche Ltd. |
| 15.2.2.Abbott Laboratories |
| 15.2.3.Thermo Fisher Scientific Inc. |
| 15.2.4.QIAGEN N.V. |
| 15.2.5.Bio-Rad Laboratories Inc. |
| 15.2.6.Illumina Inc. |
| 15.2.7.MolecularMD |
| 15.2.8.Invivoscribe Inc. |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Bio-Rad Laboratories Inc.
- Illumina Inc.
- MolecularMD
- Invivoscribe Inc.
- Asuragen Inc.
- ArcherDX Inc.